6UGU

Crystal structure of the Fab fragment of anti-TNFa antibody infliximab (Remicade) in a C-centered orthorhombic crystal form, Lot C

6UGU の概要

• エントリーDOI: 10.2210/pdb6ugu/pdb
• 分子名称: PF06438179 Fab Heavy Chain, PF06438179 Fab Light Chain (3 entities in total)
• 機能のキーワード: antibody, fab, infliximab, biosimilar, tnfa, immune system
• 由来する生物種: Homo sapiens (Human); 詳細
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 95634.10

構造登録者

Lerch, T.F.,Sharpe, P.,Mayclin, S.J.,Edwards, T.E.,Polleck, S.,Rouse, J.C.,Conlan, H.D. (登録日: 2019-09-26, 公開日: 2019-11-13, 最終更新日: 2024-10-16)

主引用文献

Lerch, T.F.,Sharpe, P.,Mayclin, S.J.,Edwards, T.E.,Polleck, S.,Rouse, J.C.,Zou, Q.,Conlon, H.D.
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar.
BioDrugs, 34:77-87, 2020

PubMed Abstract: Higher-order structure (HOS) assessment is an important component of biosimilarity evaluations. While established spectroscopic methods are routinely used to characterize structure and evaluate similarity, the addition of X-ray crystallographic analysis to these biophysical methods enables orthogonal elucidation of HOS at higher resolution.

PubMed: 31650490
DOI: 10.1007/s40259-019-00390-1

実験手法

X-RAY DIFFRACTION (2.2 Å)